On the stock market since 2024, it operates in the world of health and science. It has 3,800 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 49% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 48% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 58% a year on average.
The company sells $1.3B a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $71.33 — 33% above today’s price.
A loss of $245.0M against $1.3B in annual sales.
This stock swings about 3.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 12 months, executives reported 138 sells against just 20 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, TEM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TEM has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.